Posts by Areej R. El-Jawahri, MD
-
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that enasidenib 100 mg/day was safe and well tolerated as maintenance therapy for IDH2-mutated myeloid malignancies after hematopoietic cell transplantation and showed preliminary clinical activity.
-
Ivosidenib Shows Promise As Maintenance Therapy for AML After Bone Marrow Transplant
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that ivosidenib was safe and well tolerated as maintenance therapy for acute myeloid leukemia following allogeneic hematopoietic cell transplantation, and two-year outcomes were promising.
-
Improved Coping Explains Benefits of Integrated Palliative Care for Patients With Acute Myeloid Leukemia
Improvement of coping strategies was a key mechanism of the benefits of integrated palliative care for patients with acute myeloid leukemia who were hospitalized for intensive chemotherapy, Ashley M. Nelson, PhD, and colleagues conclude based on a secondary analysis of a randomized controlled trial.
-
Older Age Alone Should Not Rule Out Intensive Treatment of Aggressive Non-Hodgkin's Lymphoma
Massachusetts General Hospital researchers demonstrated that intensive therapy for aggressive non-Hodgkin's lymphoma has survival benefits across all age brackets of older adults, and they identified factors associated with greater risk of toxicities and unplanned hospitalization.
-
Advances in Palliative Care and the CORE Program at Mass General Cancer Center
Areej El-Jawahri, MD, explains the Massachusetts General Hospital Cancer Outcomes Research and Education Program (CORE) and discusses the advances in palliative care at Mass General Cancer Center.
-
Palliative Care Benefits Patients Undergoing Stem Cell Transplantation
Massachusetts General Hospital researchers have found that even apart from medication for symptom control, palliative care has benefits for patients facing the prolonged hospitalization required for hemopoietic stem cell transplantation.
-
Care Coordination Needed to Reduce Readmission of End-stage Liver Disease Patients
To reduce hospital readmission of patients with newly diagnosed end-stage liver disease, transitional care is needed that attends to the informational, psychosocial and practical needs of these patients and their caregivers.
-
Educational Video About Hospice Linked to Higher Utilization Rate, Longer Hospice Stay
In a randomized trial, patients with advanced cancer who were assigned to view an educational video about hospice were more likely than controls to use hospice, and their hospice stay was longer.
-
Psychosocial Intervention Promising for Caregivers of Patients Undergoing Stem Cell Transplantation
In a randomized, controlled trial conducted by the Mass General Cancer Center, a psychosocial intervention for caregivers of patients scheduled to undergo hematopoietic stem cell transplantation was feasible and showed promise for improving caregiving burden, quality of life, mood, self-efficacy and coping skills.
-
Effects of Electronic Monitoring of Cancer Symptoms Differ Based on Patient Age
Massachusetts General Hospital Cancer Center researchers find that electronic systems for monitoring cancer symptoms may need to be tailored to patients' age-specific care needs.
-
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Advance Care Planning Needed Earlier for Patients with End-stage Liver Disease
Using a web-based survey of hepatologists and gastroenterologists, Massachusetts General Hospital researchers have identified substantial barriers to palliative and end-of-life care for patients with end-stage liver disease—and they say advance care planning needs to start earlier.
Biography
Dr. El-Jawahri is an oncologist specializing in the care of patients with hematologic malignancies and those undergoing hematopoietic stem cell transplantation. Clinically, she takes care of patients with acute leukemia, myelodysplastic syndrome, chronic leukemias, lymphomas and myelomas. Her research interests include investigating patient-reported outcomes, enhancing patient-centered decision-making interventions and designing supportive care interventions to improve the care of patients with hematologic malignancies with a special emphasis on patients undergoing hematopoietic stem cell transplantation. Her research also explores models of health care delivery to improve patients' quality of life and clinical outcomes. She is an active member of the Mass General Cancer Outcomes Research and Education Program (CORE). She will also leading efforts in building and developing the Mass General Bone Marrow Transplantation Survivorship Program. She has led and conducted multiple clinical trials focusing on enhancing the experience and clinical outcomes of patients with hematologic malignancies.
Geriatrics & Palliative Care
The Division of Palliative Care & Geriatric Medicine at Massachusetts General Hospital offers a wide range of clinical expertise including inpatient services, outpatient programs and home based programs.